These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11456307)

  • 1. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell.
    Berendse HW; Booij J; Francot CM; Bergmans PL; Hijman R; Stoof JC; Wolters EC
    Ann Neurol; 2001 Jul; 50(1):34-41. PubMed ID: 11456307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic hyposmia as a preclinical sign of Parkinson's disease.
    Ponsen MM; Stoffers D; Booij J; van Eck-Smit BL; Wolters ECh; Berendse HW
    Ann Neurol; 2004 Aug; 56(2):173-81. PubMed ID: 15293269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.
    Ponsen MM; Stoffers D; Wolters ECh; Booij J; Berendse HW
    J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):396-9. PubMed ID: 19965851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease.
    Oh YS; Kim JS; Hwang EJ; Lyoo CH
    Parkinsonism Relat Disord; 2018 Nov; 56():47-51. PubMed ID: 29925486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Presymptomatic detection of Parkinson's disease].
    Berendse HW; Booij J; Stoffers D; Ponsen MM; Hijman R; Wolters ECh
    Tijdschr Gerontol Geriatr; 2002 Apr; 33(2):70-7. PubMed ID: 12012945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
    Stiasny-Kolster K; Doerr Y; Möller JC; Höffken H; Behr TM; Oertel WH; Mayer G
    Brain; 2005 Jan; 128(Pt 1):126-37. PubMed ID: 15548552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
    Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
    Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging.
    Berendse HW; Ponsen MM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S26-30. PubMed ID: 20083001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical (premotor) Parkinson's disease.
    Wolters EC; Francot C; Bergmans P; Winogrodzka A; Booij J; Berendse HW; Stoof JC
    J Neurol; 2000 Apr; 247 Suppl 2():II103-9. PubMed ID: 10991655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism.
    Bovi T; Antonini A; Ottaviani S; Antonioli A; Cecchini MP; Di Francesco V; Bassetto MA; Zamboni M; Fiaschi A; Moretto G; Sbarbati A; Osculati F; Tinazzi M
    J Neurol; 2010 Nov; 257(11):1882-9. PubMed ID: 20635186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.
    Marek KL; Seibyl JP; Zoghbi SS; Zea-Ponce Y; Baldwin RM; Fussell B; Charney DS; van Dyck C; Hoffer PB; Innis RP
    Neurology; 1996 Jan; 46(1):231-7. PubMed ID: 8559382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.